NFATc1-IN-1

NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research[1].

Product Specifications

CAS Number

[1912422-56-0]

UNSPSC

12352005

Hazard Statement

H302

Target

Nuclear Factor of activated T Cells (NFAT)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/nfatc1-in-1.html

Purity

99.97

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

OC1=C(C(NC2=C(F)C=C(I)C=C2)=O)C=C(F)C=C1

Molecular Formula

C13H8F2INO2

Molecular Weight

375.11

Precautions

H302

References & Citations

[1]Chen CL, et al. Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. Eur J Med Chem. 2016 Jul 19;117:70-84.